recombinant human il 12 (Miltenyi Biotec)

Miltenyi Biotec is a verified supplier

Miltenyi Biotec manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Miltenyi Biotec recombinant human il 12

( A ) Workflow of in vitro SATB1 KO experiments in human Treg and Tconv cells. Treg and Tconv cells were isolated from the blood of healthy donors, ex vivo expanded, CRISPR-edited, and challenged with or without <t>IL-12.</t> Cells were cultured with IL-2 throughout the experiment (Treg: 600 IU/ml; Tconv: 200 IU/ml). KO cells were phenotypically characterized by flow cytometry, bulk RNA-seq, and ATAC-seq analysis. ( B ) Heatmap displaying fold changes of pro- and anti-inflammatory flow cytometry markers in SATB1 KO Treg cells and SATB1 KO Tconv cells, normalized to their respective AAVS1 KO controls. The fold change was calculated based on the percentage of the individual marker pregated on living cells. n = 12–18 (biological replicates), ratio paired t test. ( C , D ) opt-SNE contour plot of IL-12-treated AAVS1 KO and SATB1 KO Treg ( C ) and Tconv cells ( D ). Expression levels (MFI) of tested flow cytometry markers plotted on opt-SNE plot, n = 12–18 (biological replicates). ( E ) Absolute percentages of intracellular cytokine flow cytometry stainings of IL-12-treated AAVS1 KO and SATB1 KO Treg cells. n = 12–17 (biological replicates), paired t test. ( F ) Extracellular IL-10 levels determined by LEGENDplex TM assay of IL-12-treated AAVS1 KO and SATB1 KO Treg cells. Absolute values (left), normalized to AAVS1 KO controls (right), n = 10, paired t test (left), ratio paired t test (right). ( G ) Absolute percentages of intracellular cytokine flow cytometry stainings of IL-12-treated AAVS1 KO and SATB1 KO Tconv cells. n = 12–18 (biological replicates), paired t test. ( H ) Extracellular IL-10 levels determined by LEGENDplex TM assay of IL-12 or control-treated AAVS1 KO and SATB1 KO Tconv. Absolute values (left), normalized to AAVS1 KO controls (right), n = 7 (biological replicates), paired t test (left), ratio paired t test (right). .

Recombinant Human Il 12, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 42 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/il+12/Human+IL-12%2C+premium+grade/pmc13400746-72-0-4
Average 93 stars, based on 42 article reviews

recombinant human il 12 - by Bioz Stars, 2026-11

93/100 stars

Images

1) Product Images from "SATB1 is a targetable modulator of JAK-STAT signaling and cytokines in human Treg and Tconv cells"

Article Title: SATB1 is a targetable modulator of JAK-STAT signaling and cytokines in human Treg and Tconv cells

Journal: EMBO Reports

doi: 10.1038/s44319-026-00812-6

Figure Legend Snippet: ( A ) Workflow of in vitro SATB1 KO experiments in human Treg and Tconv cells. Treg and Tconv cells were isolated from the blood of healthy donors, ex vivo expanded, CRISPR-edited, and challenged with or without IL-12. Cells were cultured with IL-2 throughout the experiment (Treg: 600 IU/ml; Tconv: 200 IU/ml). KO cells were phenotypically characterized by flow cytometry, bulk RNA-seq, and ATAC-seq analysis. ( B ) Heatmap displaying fold changes of pro- and anti-inflammatory flow cytometry markers in SATB1 KO Treg cells and SATB1 KO Tconv cells, normalized to their respective AAVS1 KO controls. The fold change was calculated based on the percentage of the individual marker pregated on living cells. n = 12–18 (biological replicates), ratio paired t test. ( C , D ) opt-SNE contour plot of IL-12-treated AAVS1 KO and SATB1 KO Treg ( C ) and Tconv cells ( D ). Expression levels (MFI) of tested flow cytometry markers plotted on opt-SNE plot, n = 12–18 (biological replicates). ( E ) Absolute percentages of intracellular cytokine flow cytometry stainings of IL-12-treated AAVS1 KO and SATB1 KO Treg cells. n = 12–17 (biological replicates), paired t test. ( F ) Extracellular IL-10 levels determined by LEGENDplex TM assay of IL-12-treated AAVS1 KO and SATB1 KO Treg cells. Absolute values (left), normalized to AAVS1 KO controls (right), n = 10, paired t test (left), ratio paired t test (right). ( G ) Absolute percentages of intracellular cytokine flow cytometry stainings of IL-12-treated AAVS1 KO and SATB1 KO Tconv cells. n = 12–18 (biological replicates), paired t test. ( H ) Extracellular IL-10 levels determined by LEGENDplex TM assay of IL-12 or control-treated AAVS1 KO and SATB1 KO Tconv. Absolute values (left), normalized to AAVS1 KO controls (right), n = 7 (biological replicates), paired t test (left), ratio paired t test (right). .

Techniques Used: In Vitro, Isolation, Ex Vivo, CRISPR, Cell Culture, Flow Cytometry, RNA Sequencing, Marker, Expressing, Control

Human Treg and Tconv cells were isolated, expanded, activated, and nucleofected with Cas9 RNPs targeting AAVS1 , FOXP3 , and SATB1 . The cells were cultured with or without the pro-inflammatory cytokine IL-12. ( A ) Scatter dot plot displaying KO efficiencies with median. KO efficiencies were determined by amplicon NGS sequencing and TIDE analysis. n = 2–9 (biological replicates). ( B ) Bar graphs indicate the mean of relative mRNA expression (ΔCt) of SATB1 and FOXP3 in AAVS 1 and SATB1 KO Treg cells normalized to 18S rRNA levels. RNA of FACS-sorted living cells was isolated, and qPCR was performed in technical duplicates. n = 4–5 (biological replicates), paired t test. ( C ) Flow cytometry analysis of canonical pro- and anti-inflammatory markers in FOXP3 KO Treg cells stimulated with or without IL-12. Percentages of marker-positive cells were normalized to the respective AAVS1 KO Treg cells with or without IL-12 stimulation. n = 6–7 (biological replicates), ratio paired t test. ( D ) Flow cytometry gating strategy of AAVS1 KO control Treg and Tconv cells without IL-12 conditioning. ( E ) Bar graph plots quantifying flow cytometry marker expressions of AAVS1 , FOXP3 , and SATB1 KO Treg cells treated with or without IL-12. Data are also partially shown in Fig. . n = 6–17 (biological replicates), paired t test. ( F ) Bar graph plots quantifying flow cytometry marker expressions of AAVS1 and SATB1 KO Tconv cells treated with or without IL-12. Data are also partially shown in Fig. . n = 12–18 (biological replicates), paired t test.

Figure Legend Snippet: Human Treg and Tconv cells were isolated, expanded, activated, and nucleofected with Cas9 RNPs targeting AAVS1 , FOXP3 , and SATB1 . The cells were cultured with or without the pro-inflammatory cytokine IL-12. ( A ) Scatter dot plot displaying KO efficiencies with median. KO efficiencies were determined by amplicon NGS sequencing and TIDE analysis. n = 2–9 (biological replicates). ( B ) Bar graphs indicate the mean of relative mRNA expression (ΔCt) of SATB1 and FOXP3 in AAVS 1 and SATB1 KO Treg cells normalized to 18S rRNA levels. RNA of FACS-sorted living cells was isolated, and qPCR was performed in technical duplicates. n = 4–5 (biological replicates), paired t test. ( C ) Flow cytometry analysis of canonical pro- and anti-inflammatory markers in FOXP3 KO Treg cells stimulated with or without IL-12. Percentages of marker-positive cells were normalized to the respective AAVS1 KO Treg cells with or without IL-12 stimulation. n = 6–7 (biological replicates), ratio paired t test. ( D ) Flow cytometry gating strategy of AAVS1 KO control Treg and Tconv cells without IL-12 conditioning. ( E ) Bar graph plots quantifying flow cytometry marker expressions of AAVS1 , FOXP3 , and SATB1 KO Treg cells treated with or without IL-12. Data are also partially shown in Fig. . n = 6–17 (biological replicates), paired t test. ( F ) Bar graph plots quantifying flow cytometry marker expressions of AAVS1 and SATB1 KO Tconv cells treated with or without IL-12. Data are also partially shown in Fig. . n = 12–18 (biological replicates), paired t test.

Techniques Used: Isolation, Cell Culture, Amplification, Sequencing, Expressing, Flow Cytometry, Marker, Control

( A , B ) opt-SNE plot of untreated or IL-12-treated AAVS1 KO Treg ( C ) and Tconv cells ( D ). ( C , D ) Expression levels (MFI) of tested flow cytometry markers of untreated AAVS1 KO and SATB1 KO Treg ( A ) and Tconv cells ( B ) plotted on opt-SNE density plot. n (Treg) = 12–17 (biological replicates), n (Tconv) = 12–18 (biological replicates).

Figure Legend Snippet: ( A , B ) opt-SNE plot of untreated or IL-12-treated AAVS1 KO Treg ( C ) and Tconv cells ( D ). ( C , D ) Expression levels (MFI) of tested flow cytometry markers of untreated AAVS1 KO and SATB1 KO Treg ( A ) and Tconv cells ( B ) plotted on opt-SNE density plot. n (Treg) = 12–17 (biological replicates), n (Tconv) = 12–18 (biological replicates).

Techniques Used: Expressing, Flow Cytometry

( A ) Venn diagram of differentially accessible chromatin regions in SATB1 KO Treg and Tconv cells normalized to AAVS1 KO control cells ( P value < 0.05, Wald test using DESeq2). ( A , B ) n = 3 (biological replicates). ( B ) PCA plot of AAVS1 and SATB1 KO Treg and Tconv cells treated with IL-12, analyzed by ATAC-seq. ( C ) Venn diagram of differentially expressed genes in SATB1 KO Treg and Tconv cells normalized to AAVS1 KO control cells ( P value < 0.05, Wald test using DESeq2). ( D ) PCA plot of AAVS1 and SATB1 KO Treg and Tconv cells analyzed by RNA-seq after IL-12 conditioning. ( E ) Heatmaps indicating log2 fold change of overlapping RNA-seq data of SATB1 KO Treg and Tconv cells treated with IL-12. Human transcription factors were indicated in bold. ( C – E ) n = 3 (biological replicates). .

Figure Legend Snippet: ( A ) Venn diagram of differentially accessible chromatin regions in SATB1 KO Treg and Tconv cells normalized to AAVS1 KO control cells ( P value < 0.05, Wald test using DESeq2). ( A , B ) n = 3 (biological replicates). ( B ) PCA plot of AAVS1 and SATB1 KO Treg and Tconv cells treated with IL-12, analyzed by ATAC-seq. ( C ) Venn diagram of differentially expressed genes in SATB1 KO Treg and Tconv cells normalized to AAVS1 KO control cells ( P value < 0.05, Wald test using DESeq2). ( D ) PCA plot of AAVS1 and SATB1 KO Treg and Tconv cells analyzed by RNA-seq after IL-12 conditioning. ( E ) Heatmaps indicating log2 fold change of overlapping RNA-seq data of SATB1 KO Treg and Tconv cells treated with IL-12. Human transcription factors were indicated in bold. ( C – E ) n = 3 (biological replicates). .

Techniques Used: Control, RNA Sequencing

( A ) Mean fluorescence intensity (MFI) of GATA3 expression of SATB1 KO and AAVS1 control KO Treg and Tconv cells treated with or without IL-12. n = 6–9 (biological replicates), paired t test. ( B ) Mean fluorescence intensity (MFI) of CD86 and FOXP3 expression of SATB1 KO and AAVS1 control KO Treg and Tconv cells treated with or without IL-12. n = 8–9 (biological replicates), paired t test. ( C , D ) AAVS1 and SATB1 KO Tconv cell expansion rate at day 14, 15, 16, and 18 of culture with or without the addition of IL-12. ( C ) Absolute cell counts with mean and SD, ( D ) cell counts of SATB1 KO Tconv cells normalized to respective AAVS1 KO control cells. n = 6 (biological replicates). ( E , F ) Extracellular IL-6 levels determined by LEGENDplex TM assay of IL-12-treated AAVS1 KO and SATB1 KO Treg ( E ) or Tconv cells ( F ). Absolute values (left), normalized to AAVS1 KO controls (right), n = 7–10 (biological replicates), paired t test.

Figure Legend Snippet: ( A ) Mean fluorescence intensity (MFI) of GATA3 expression of SATB1 KO and AAVS1 control KO Treg and Tconv cells treated with or without IL-12. n = 6–9 (biological replicates), paired t test. ( B ) Mean fluorescence intensity (MFI) of CD86 and FOXP3 expression of SATB1 KO and AAVS1 control KO Treg and Tconv cells treated with or without IL-12. n = 8–9 (biological replicates), paired t test. ( C , D ) AAVS1 and SATB1 KO Tconv cell expansion rate at day 14, 15, 16, and 18 of culture with or without the addition of IL-12. ( C ) Absolute cell counts with mean and SD, ( D ) cell counts of SATB1 KO Tconv cells normalized to respective AAVS1 KO control cells. n = 6 (biological replicates). ( E , F ) Extracellular IL-6 levels determined by LEGENDplex TM assay of IL-12-treated AAVS1 KO and SATB1 KO Treg ( E ) or Tconv cells ( F ). Absolute values (left), normalized to AAVS1 KO controls (right), n = 7–10 (biological replicates), paired t test.

Techniques Used: Fluorescence, Expressing, Control

( A , B ) Volcano plot of differentially accessible chromatin regions of SATB1 KO Treg versus AAVS1 KO Treg cells ( A ) and SATB1 KO Tconv versus AAVS1 KO Tconv cells ( B ), n = 3 (biological replicates). Genes with a P value < 0.05 are highlighted, calculated by a Wald test using DESeq2. ( C , D ) Volcano plot of differentially expressed genes of SATB1 KO Treg versus AAVS1 KO Treg cells ( C ) and SATB1 KO Tconv versus AAVS1 KO Tconv cells ( D ), n = 3 (biological replicates). Genes with a P value < 0.05 are highlighted, calculated by a Wald test using DESeq2. ( E ) Heatmaps displaying z-scores of equally regulated chromatin and gene expression changes in SATB1 KO Treg and Tconv cells treated with IL-12. Differentially regulated TFs are highlighted in purple. Top hits of Reactome (REAC) and biological pathway (BP) analysis and associated adjusted P values ( P adj) if significant are highlighted. n = 3 (biological replicates). .

Figure Legend Snippet: ( A , B ) Volcano plot of differentially accessible chromatin regions of SATB1 KO Treg versus AAVS1 KO Treg cells ( A ) and SATB1 KO Tconv versus AAVS1 KO Tconv cells ( B ), n = 3 (biological replicates). Genes with a P value < 0.05 are highlighted, calculated by a Wald test using DESeq2. ( C , D ) Volcano plot of differentially expressed genes of SATB1 KO Treg versus AAVS1 KO Treg cells ( C ) and SATB1 KO Tconv versus AAVS1 KO Tconv cells ( D ), n = 3 (biological replicates). Genes with a P value < 0.05 are highlighted, calculated by a Wald test using DESeq2. ( E ) Heatmaps displaying z-scores of equally regulated chromatin and gene expression changes in SATB1 KO Treg and Tconv cells treated with IL-12. Differentially regulated TFs are highlighted in purple. Top hits of Reactome (REAC) and biological pathway (BP) analysis and associated adjusted P values ( P adj) if significant are highlighted. n = 3 (biological replicates). .

Techniques Used: Gene Expression

Heatmaps display z-scores of RNA- and ATAC-seq data of SATB1 KO and AAVS1 KO Treg and Tconv cells treated with IL-12. TFs differently regulated in RNA- and ATAC-seq data after SATB1 KO are highlighted in purple. Genes associated with “Interleukin-10 signaling”, “Positive regulation of leukocyte proliferation”, or “cytokine-mediated signaling” are highlighted. REAC Reactome, BP biological pathway. n = 3 (biological replicates).

Figure Legend Snippet: Heatmaps display z-scores of RNA- and ATAC-seq data of SATB1 KO and AAVS1 KO Treg and Tconv cells treated with IL-12. TFs differently regulated in RNA- and ATAC-seq data after SATB1 KO are highlighted in purple. Genes associated with “Interleukin-10 signaling”, “Positive regulation of leukocyte proliferation”, or “cytokine-mediated signaling” are highlighted. REAC Reactome, BP biological pathway. n = 3 (biological replicates).

Techniques Used:

Differently expressed genes (DEGs) of the cytokine–cytokine receptor pathway ( A ) and the JAK-STAT signaling pathway ( B ) in SATB1 KO Treg and Tconv cells treated with IL-12, normalized to the respective IL-12 AAVS1 KO conditions based on RNA-seq data. Color scheme indicates log2 fold changes of gene expression and the size of the dots the -log10 of the P value calculated by a Wald test using DESeq2, n = 3 (biological replicates). .

Figure Legend Snippet: Differently expressed genes (DEGs) of the cytokine–cytokine receptor pathway ( A ) and the JAK-STAT signaling pathway ( B ) in SATB1 KO Treg and Tconv cells treated with IL-12, normalized to the respective IL-12 AAVS1 KO conditions based on RNA-seq data. Color scheme indicates log2 fold changes of gene expression and the size of the dots the -log10 of the P value calculated by a Wald test using DESeq2, n = 3 (biological replicates). .

Techniques Used: RNA Sequencing, Gene Expression

Recombinant:

Article Title: SATB1 is a targetable modulator of JAK-STAT signaling and cytokines in human Treg and Tconv cells
Article Snippet: Recombinant human IL-2 , Peprotech , Cat#: 200-02. .. Recombinant human IL-12 , Miltenyi , Cat#: 130-096-704. .. MojoSortTM Human CD4 T cell Isolation Kit , BioLegend , Cat#: 480130.

Article Title: Age-Related Patterns of Type II Interferon Immunity: Implications for Intramacrophagic Infections and MSMD Diagnosis During Childhood
Article Snippet: Panel Surface marker Fluorocrom Company Catalog Number Volume/ Test (μL) T cells TCR αβ FITC BD 333140 2 TCR γδ PE BD 333141 2 CD8 PerCP-Cy5.5 BD 565310 2 CD45RA Pe-Cy7 BD 337186 2 CD45RO APC BD 340438 2 CD4 APC BD 345771 2 CD3 APC-H7 BD 641415 2 HLA-DR V450 BD 655874 2 CCR7 BV510 BD 566760 2 T helper cells CD4 FITC BD 345768 2 CXCR3 PE BD 550633 10 CD8 PerCP-Cy5.5 BD 565310 2 CCR6 Pe-Cy7 BD 560620 2 CD45RO APC BD 340438 2 CD45RA APC-H7 BD 561212 2 CD3 V450 BD 560365 2 CXCR5 BV510 BD 563105 2 IFNγ receptors IFNγR1 PE BD 558937 2 IFNγR2 APC R&D systems FAB773A 10 STAT1 phosphorylation dephosphorilation STAT 1 PE BD 612564 6 CD14 APC BD 555399 6 T cell proliferation assay CD4 FITC BD 345768 2 CD19 Pe-Cy7 BD 557835 2 CD3 APC-H7 BD 641415 2 .. Assay Reagent name Company Catalog number Test* Flow cytometry lysing Lyse solution BD 349202 2mL IL-12/IFN-γ axis culture BCG - - 20 BCG/leukocyte hrL-12p70 Miltenyi Biotec 130-096- 798 20 ng/ml hrIFN-γ Imukin Boehringer Ingelheim - 5,000 IU/ml TNF Miltenyi Biotec 130-094- 014 10 μg/mL PMA Sigma Aldrich P81391MG 50 ng/mL Ionomycin Sigma Aldrich i06341MG 1 ug/mL T cell proliferation CFSE Invitrogen C34554 5μM IL-2 Hospital Clínic pharmacy - 1,250 IU/mL PHA Sigma Aldrich L16685MG 5μg/mL ConA Sigma Aldrich C52755MG 2 μg/mL PWM Sigma Aldrich L877710MG 2 μg/mL Luminex: Human Cytokine Magnetic Bead Panel Millipore HCYTOMAG-60K MI IFN-γ levels IFN-γ Human Uncoated ELISA Kit Invitrogen 88-7316-88 MI Tween Millipore 9005-64-5 0.05% STAT1 activity Lyse/Fix Buffer 5x BD 558049 500μL Perm Buffer III BD 558050 500μL Human recombinant IFN-γ, Imukin Boehringer Ingelheim - 102 and 104 IU/mL Pegasys (peginterferon α) Pegasys, Roche - 10 3 IU/mL Test*: volume or concentration/test. .. Abbreviations: BCG: bacille calmette-guérin; BD: Becton Dickinson (company); CFSE: carboxifluorescein diacetate succinimidyl ester; ConA: concavalin

Article Title: Vδ2 T cell activation by malaria is enhanced in second infection via the cell extrinsic cytokine milieu
Article Snippet: Sorted naive CD4 + T cells were labelled with 5 μM of CellTrace Violet (1/2500; Biolegend #CD34557A) in PBS for 20 minutes in a 37°C, quenched for 10 minutes in R10 before being used as responder cells in the mixed lymphocyte reaction. .. 5 x 10 4 isolated naive CD4 T cells ( n = 12) were combined in an allogenic mixed lymphocyte reaction with 10 5 isolated γδ T cells ( n = 6) ex vivo , and from media, uRBC or pRBC cultures, and with Human T-Activator CD3/CD28 DynabeadsTM (Gibco, Cat. #11161D) plus recombinant cytokines 1ng/mL IL-12 (Miltenyi Biotec; Cat. #130-096- 704), 25ng/mL IL-23 (Miltenyi Biotec; Cat. #130-095-757) and 5ng/mL TGF-β1(Miltenyi Biotec; #130-095-067) for 6 days at 37°C, 5% CO2 R10 supplemented with 100 IU/mL IL-2 . ..

Flow Cytometry:

Enzyme-linked Immunosorbent Assay:

Activity Assay:

Concentration Assay:

Isolation:

Ex Vivo:

other:

Article Title: Circulating natural killer cells are phenotypically and functionally altered in age-related macular degeneration.
Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Fetal Bovine Serum (FBS) Merck Cat# F9665-500ML Pen-Strep Merck Cat# P4333-100ML OCT mounting media VWR Cat# 361603E MMLV reverse transcriptase Promega Cat# PAM5313 10nm Random Hexamers IDT Cat# 51-01-18-25 RNaseOUTTM Recombinant Ribonuclease Inhibitor Invitrogen Cat# 10777019 RPMI Merck Cat# R8758-500ML Myo-Inositol Sigma Cat# I7508-50G L-Glutamine Sigma Cat# G8540-10MG Folic Acid Sigma Cat# F7876-1G Horse Serum Sigma Cat# H1270-500ML LIVE/DEADTM Fixable Aqua Dead Cell Stain Kit, for 405 nm excitation Thermo Fisher Cat# L34957 Proteinase K Thermo Fisher Cat# EO0491 Ethidium Bromide solution Thermo Fisher Cat# 17898 HBSS BioSciences Cat# 14025050 HEPES Buffer Merck Cat# C-40010 DNAse I Merck Cat# 10104159001 Bovine Serum Albumin Merck Cat# 05470 Protease Inhibitor Cocktail Merck Cat# P8340 Triton X-100 Merck Cat# 93422 Endothelial Cell Growth Medium MV2 Kit Merck Cat# C-22121 Lymphoprep Stemcell Technologies Cat# 18061 Hyclone Trypan Blue Thermo Fischer Cat# SV3008401 Murine Recombinant IL-18 GSK/Biotechne Cat# 9139-IL * Human Recombinant IL-18 Biotechne Cat# 9124-IL Human IL-12 Miltenyi Biotec Cat# 130-096-705 Recombinant Mouse IL-12 Biotechne Cat# 419-ML Human IL-15 Miltenyi Biotec Cat# 130-095-760 Murine Recombinant IL-15 Peprotech® Cat# 210-15-10UG BD Cytofix/CytoPerm BD Biosciences Cat# 554722; RRID: AB_2869010 BD GolgiPlug BD Biosciences Cat# 15847968 Incucyte® Caspase-3/7 Dye for Apoptosis Sartorius Cat# 4440 Etoposide Thermo Fisher Cat# J63651.MB Oligomycin Sigma Cat# O4876 Rotenone Sigma Cat# 557368 Antimycin Sigma Cat# A8674 2-deoxyglucose Sigma Cat# D8375 Critical commercial assays E.Z.N.A.® Total RNA Kit I Omega-BIO-TEK Cat# R6834-02 SensiFASTTM SYBR® No-ROX Kit Bioline/Meridian Bioscience Cat# BIO-98020 Mouse NK Cell Isolation Kit Miltenyi Cat# 130-115-818 CyQuant LDH Cytotoxicity Assay Life Technologies Cat# C20301 Deposited data Mouse liCNV scRNA-seq This paper GEO: GSE318755 Mouse IL-18 scRNA-seq datset This paper GEO: GSE317763 (Continued on next page) Cell Reports Medicine 7, 102792, June 16, 2026 e2 Article ll OPEN ACCESS

Multiplex Assay:

Article Title: Tumor-Infiltrating Natural Killer Cell Characterization in Pancreatic Ductal Adenocarcinoma
Article Snippet: .. Each well contained 1 mL of media (Cell Genix GMP #20801-0500, and multiplex immunofluorescence (mIF) Götingen, Germany) with 10% human serum (Sigma-Aldrich #H4522, Burlington, MA, USA), 1% Penicillin/Streptomycin (Corning #30-002, Tewksbury, MA, USA), 1 μg/mL Clindamycin (Fresenius Kabi #10030860, Bad Homburg vor der Höhe, Germany), 1 μg/mL Amphotericin (Sigma-Aldrich #A2942, Burlington, MA, USA) and 10 μg/mL Ciprofloxacin (Fresenius Kabi #10071960, Bad Homburg vor der Höhe, Germany), as well as IL-2 (1000 IU/mL, Miltenyi #130-097-746, Bergisch Gladbach, Germany), IL-12 (10 IU/mL, Miltenyi #130-096-798, Bergisch Gladbach, Germany), and IL-15 (180 IU/mL, Miltenyi #130-095-765, Bergisch Gladbach, Germany). ..